|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ovarian Neoplasms | |||||
| Peritoneal Neoplasms | |||||
| Fallopian Tube Neoplasms | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Abdominal Neoplasms | |||||
| Adnexal Diseases | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Fallopian Tube Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms by Site | |||||
| Ovarian Diseases | |||||
| Peritoneal Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| epothilone b | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Epothilones | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antimitotic Agents | |||||
| Antineoplastic Agents | |||||
| Mitosis Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| Tubulin Modulators | |||||
| 7 | Sponsors listed in this trial | ||||
| Novartis | |||||